Mitochondria-Related ITFAM/I and IPOLG/I Gene Variants and Associations with Tumor Characteristics and Patient Survival in Head and Neck Cancer

• Published in: Genes 2023-02, Vol.14 (2)
• Main Authors: Golubickaite, Ieva, Ugenskiene, Rasa, Bartnykaite, Agne, Poskiene, Lina, Vegiene, Aurelija, Padervinskis, Evaldas, Rudzianskas, Viktoras, Juozaityte, Elona
• Format: Article
• Language: English
• Subjects: Analysis; DNA polymerases; Genetic aspects; Head and neck cancer; Mitochondria; Patient outcomes; Physiological aspects; Single nucleotide polymorphisms; Transcription factors
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes14020434

In 2020, 878,348 newly reported cases and 444,347 deaths related to head and neck cancer were reported. These numbers suggest that there is still a need for molecular biomarkers for the diagnosis and prognosis of the disease. In this study, we aimed to analyze mitochondria-related mitochondrial transcription factor A (TFAM) and DNA polymerase γ (POLG) single-nucleotide polymorphisms (SNPs) in the head and neck cancer patient group and evaluate associations between SNPs, disease characteristics, and patient outcomes. Genotyping was performed using TaqMan probes with Real-Time polymerase chain reaction. We found associations between TFAM gene SNPs rs11006129 and rs3900887 and patient survival status. We found that patients with the TFAM rs11006129 CC genotype and non-carriers of the T allele had longer survival times than those with the CT genotype or T-allele carriers. Additionally, patients with the TFAM rs3900887 A allele tended to have shorter survival times than non-carriers of the A allele. Our findings suggest that variants in the TFAM gene may play an important role in head and neck cancer patient survival and could be considered and further evaluated as prognostic biomarkers. However, due to the limited sample size (n = 115), further studies in larger and more diverse cohorts are needed to confirm these findings.